Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing

1. A double-stranded nucleic acid molecule targeting a sequence selected from the group consisting of: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, wherein the double-stranded nucleic acid comprises a single strand from 19 to 56 nucleotides in length comprising a sequence selected from the group consisting of:

(SEQ ID NO: 5)

5′-GGAAGUAAGCUCAGGAUCUCAGCAG-3;

(SEQ ID NO: 6)

5′-GUCCUUCAUUCGAGUCCUAUAGUCGUC-3′;

(SEQ ID NO: 7)

5′-CACAUGAUGCCUGCUAGUU-3′;

and

(SEQ ID NO: 8)

5′-GACACUUUCUUCAUGAGCA-3′,

or a sequence fully complementary thereto.

2. A composition comprising the nucleic acid molecule of claim 1 and a pharmaceutically acceptable carrier or additive.

3. The composition of claim 2 , wherein said carrier or additive comprises at least one of the following: hydrogel/sugar, a lipid, a cream, a gel, and a nanoparticle.

4. The composition of claim 3 , wherein the nanoparticle is a liposomal nanoparticle.

5. The composition of claim 3 , wherein said carrier comprises at a viral vector.

6. The composition of claim 3 , wherein said carrier comprises at least one of the following: a cationic lipid, a hydrophilic polymer.

7. The composition of claim 6 , wherein the hydrophilic polymer is polylactic acid and glycolic acid (PLGA) or PEG.

8. A method of treating or reducing metastasis in a subject having a cancer, comprising administering a therapeutically effective amount of the composition of claim 2 , or a composition comprising, to said subject.

9. The method of claim 8 , wherein the cancer is a thyroid, blood, bladder, breast, colorectal, kidney, lung, melanoma, ovary, pancreas, prostate or stomach cancer.

10. A method of reducing or inhibiting fibrosis in a subject comprising administering a therapeutically effective amount of the composition of claim 2 , to said subject.

11. The method of claim 10 , wherein the fibrosis is a fibroma, pulmonary fibrosis, cystic fibrosis, hepatic cirrhosis, endomyocardial fibrosis, from a previous myocardial infarction, atrial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis of the lungs, a complication of pneumoconiosis, nephrogenic systemic fibrosis, Crohn's disease fibrosis, keloid fibrosis, scleroderma/systemic sclerosis of skin or lungs, arthrofibrosis or adhesive capsulitis fibrosis.

12. A method of reducing or inhibiting scarring in a subject comprising administering a therapeutically effective amount of the composition of claim 2 , to said subject.

13. The method of claim 12 , wherein the scarring is skin scarring, cardiovascular scarring, cardiac tissue scarring, or neuronal scarring.

14. A method of reducing pain associated with wound healing in a subject comprising administering a therapeutically effective amount of the composition of claim 2 that is from the group consisting of SEQ ID NOS:7-8 to said subject.

15. The method of claim 14 , wherein the wound is a skin wound, cardiovascular wound, a cardiac tissue wound, or neuronal wound.